CORCEPT THERAPEUTICS INC (CORT) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $14.91M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $14.91M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $14.91M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 182.93M USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Amounts owed to suppliers | 14.91M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | Deferred Revenue, Current |
| Deferred revenue due within one year | (m) | Deferred Revenue, Current |
| Deferred revenue due after one year | (m) | Deferred Revenue, Current |
| Reported other obligations due within one year | (m) | Other Liabilities, Current |
| Reported other noncurrent obligations | (m) | |
| Deferred revenue included in other noncurrent obligations | (m) | Deferred Revenue, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $9.42M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $14.91M | (m) | (m) | (m) | $182.93M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $33.31M | (m) | (m) | (m) | $176.89M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $40.44M | (m) | (m) | (m) | $188.85M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $34.45M | (m) | (m) | (m) | $191.71M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $23.52M | (m) | (m) | (m) | $165.93M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $27.95M | (m) | (m) | (m) | $163.17M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $15.38M | (m) | (m) | (m) | $160.96M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $18.58M | (m) | (m) | (m) | $145.42M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $19.48M | (m) | (m) | (m) | $118.31M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $12.56M | (m) | (m) | (m) | $108.07M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $17.40M | (m) | (m) | (m) | $114.81M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $16.71M | (m) | (m) | (m) | $132.34M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $7.98M | (m) | (m) | (m) | $103.01M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $11.22M | (m) | (m) | (m) | $88.26M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $11.98M | (m) | (m) | (m) | $81.59M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $8.18M | (m) | (m) | (m) | $59.89M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $8.25M | (m) | (m) | (m) | $54.04M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $9.27M | (m) | (m) | (m) | $60.31M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $6.91M | (m) | (m) | (m) | $47.95M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $6.56M | (m) | (m) | (m) | $45.17M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $9.22M | (m) | (m) | (m) | $45.80M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $6.97M | (m) | (m) | (m) | $41.60M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $10.55M | (m) | (m) | (m) | $48.39M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $6.51M | (m) | (m) | (m) | $44.45M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $6.30M | (m) | (m) | (m) | $44.13M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $4.98M | (m) | (m) | (m) | $36.01M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $7.54M | (m) | (m) | (m) | $41.13M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $5.94M | (m) | (m) | (m) | $32.65M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $7.03M | (m) | (m) | (m) | $30.63M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $9.33M | (m) | (m) | (m) | $34.46M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $8.27M | (m) | (m) | (m) | $35.81M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $13.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $6.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $7.85M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $8.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $6.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $2.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $4.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $2.29M | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2016-09-30 | (m) | $4.31M | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2016-06-30 | (m) | $2.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $2.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $1.32M | (m) | (m) | (m) | (m) | (m) | $158.00K | (m) | (m) | (m) |
| 2015-09-30 | (m) | $1.74M | (m) | (m) | (m) | (m) | (m) | $79.00K | (m) | (m) | (m) |
| 2015-06-30 | (m) | $2.36M | (m) | (m) | (m) | (m) | (m) | $37.00K | (m) | (m) | (m) |
| 2015-03-31 | (m) | $1.04M | (m) | (m) | (m) | (m) | (m) | $55.00K | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.89M | (m) | (m) | (m) | (m) | (m) | $33.00K | (m) | (m) | (m) |
| 2014-09-30 | (m) | $1.96M | (m) | (m) | (m) | (m) | (m) | $50.00K | (m) | (m) | (m) |
| 2014-06-30 | (m) | $2.60M | (m) | (m) | (m) | (m) | (m) | $44.00K | (m) | (m) | (m) |
| 2014-03-31 | (m) | $3.67M | (m) | (m) | (m) | (m) | (m) | $29.00K | (m) | (m) | (m) |
| 2013-12-31 | (m) | $2.38M | (m) | (m) | (m) | (m) | (m) | $25.00K | (m) | (m) | (m) |
| 2013-09-30 | (m) | $2.34M | (m) | (m) | (m) | (m) | (m) | $55.00K | (m) | (m) | (m) |
| 2013-06-30 | (m) | $3.03M | (m) | (m) | (m) | (m) | (m) | $37.00K | (m) | (m) | (m) |
| 2013-03-31 | (m) | $2.26M | (m) | (m) | (m) | (m) | (m) | $76.00K | (m) | (m) | (m) |
| 2012-12-31 | (m) | $3.80M | (m) | (m) | (m) | (m) | (m) | $16.00K | (m) | (m) | (m) |
| 2012-09-30 | (m) | $1.57M | (m) | (m) | (m) | (m) | (m) | $21.00K | (m) | (m) | (m) |
| 2012-06-30 | (m) | $4.24M | (m) | $621.00K | (m) | (m) | (m) | $26.00K | (m) | (m) | (m) |
| 2012-03-31 | (m) | $2.08M | (m) | $441.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $3.61M | (m) | $533.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $1.07M | (m) | $660.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $2.29M | (m) | $552.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $817.00K | (m) | $422.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |